Cardiovascular benefit of colchicine in relation to baseline risk

30 August 2024 (08:00 - 17:30)

Organised by:

Sign in for access options

Sign in for access options

About the speaker

Mr N Mohammadnia

Radboud University Medical Centre, Nijmegen (Netherlands (The))

7 More presentations in this session

Presentation thumbnail

Low-dose interleukin-2 for the reduction of vascular inflammation in acute coronary syndromes (IVORY) / IVORY - Clinical Outcomes And Follow-up (IVORY FINALE) Study

Doctor R. Sriranjan (Cambridge, GB)

Presentation thumbnail

Anakinra versus placebo double blind Randomized controlled trial for the treatment of Acute MyocarditIS

Professor M. Kerneis (Paris, FR)

Presentation thumbnail

Colchicine for secondary prevention of stroke and other cardiovascular events: a meta-analysis of randomised trials

Doctor A. Fiolet (Utrecht, NL)

Presentation thumbnail

Effect of pre-hospital pulse-dose glucocorticoid on infarct size in st-segment elevation myocardial infarction: a randomized, blinded, placebo-controlled clinical trial

Doctor J. Marquard (Copenhagen, DK)

Presentation thumbnail

Randomized double-blind trial to study the benefit of Colchicine in Patients with Acutely Decompensated Heart Failure

Professor D. Pascual Figal (Murcia, ES)

Access the full session

Session thumbnail

Smaller trials, trial updates, and other studies on inflammation and immunity in cardiovascular disease

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024

You may be interested in

Congress Presentation

Making personalised prevention everyone's business

Congress Presentation

Should we intervene early in patients with asymptomatic aortic stenosis?

Congress Presentation

Cardiovascular prevention in older adults

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources